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Infection and autoimmunity are two common patho-
logical processes, during which inflammation might be 
elicited in an organ-specific manner. Microorganisms 
can infect specific organs and induce inflammatory 
responses. Frequently, the host immune response against 
the invading pathogens may also cause tissue damage 
owing to bystander effects. Moreover, inflammation can 
sometimes trigger organ-specific autoimmune diseases 
or even malignant transformation of the affected organ.
Among the many cell types of the immune system, 
natural killer cells (NK cells) are one of the earliest cell 
types to arrive at target organs of inflammation1. The 
role of NK cells in modulating inflammatory responses 
in different organs is often complex, not always com-
pletely understood and sometimes even paradoxical2–4. 
For example, some studies have shown that NK cells 
may promote insulitis, destroy insulin-producing islet 
cells and promote the development of type 1 diabetes 
(T1D)5–8. In sharp contrast, other studies have shown 
that NK cells may inhibit the intensity of inflammatory 
responses within the central nervous system (CNS)9–12. 
In rheumatoid arthritis, however, both inhibitory and 
promoting roles for NK cells have been reported13,14. 
Although different NK cell subsets or functions might 
be involved during different stages of the inflamma-
tory process2,3, emerging evidence indicates that addi-
tional elements, such as organ-specific factors and 
cellular interactions, may also influence the divergent 
functions of NK cells in different organs and during 
different pathological conditions.
Bone marrow-derived NK cell precursors undergo 
a maturation process that leads to the acquisition of 
their effector functions, changes in the expression of 
chemotactic receptors and adhesion molecules, and their 
migration from the bone marrow through the blood to 
the spleen, liver, lung and many other organs. The dis-
tribution of NK cells is not static because these cells can 
recirculate between organs15. Owing to the expression of 
chemokine receptors, such as CC-chemokine receptor 2 
(CCR2), CCR5, CXC-chemokine receptor 3 (CXCR3) 
and CX3C-chemokine receptor 1 (CX3CR1), NK cells 
can respond to a large array of chemokines16, and thus 
they can be recruited to distinct sites of inflammation17–25 
and extravagate to the parenchyma or body cavities. In 
contrast to B cells, T cells and dendritic cells (DCs), the 
detailed trafficking patterns of NK cells are not very well 
characterized. Nevertheless, it appears that chemokines 
produced by cells that are unique to specific organs 
may have a role in orchestrating NK cell migration to 
each organ. For example, the CX3C-chemokine ligand 1 
(CX3CL1; also known as fractalkine) produced by neu-
rons is necessary and sufficient to guide CX3CR1-bearing 
NK cells to the inflamed brain10,26. Similarly, Kupffer cell-
derived CC-chemokine ligand 2 (CCL2; also known as 
MCP1) attracts CCR2-expressing NK cells to the liver 
during murine cytomegalovirus (MCMV) infection27,28. 
The production of unique chemokines by organ-specific 
cell types for the recruitment of NK cells (TABLE 1) sug-
gests that organ-intrinsic elements may be important 
in shaping NK cell homing during physiological and 
pathological conditions.
In this article, we discuss recent research on organ-
specific NK cells and argue that organ-intrinsic factors 
shape the cellular, molecular and functional features of 
NK cells in organ-specific inflammation. The impact of 
the local environment in tumours on NK cells will not 
be discussed here because this topic has been extensively 
covered elsewhere29,30.
*Department of Neurology, 
Tianjin Neurological Institute, 
Tianjin Medical University 
General Hospital, Tianjin 
300052, China.
‡Department of Neurology, 
Barrow Neurological Institute, 
St. Joseph’s Hospital and 
Medical Center, Phoenix, 
Arizona 85013, USA.
§Center for Infectious 
Medicine, Department of 
Medicine, Karolinska 
Institutet, Karolinska 
University Hospital Huddinge, 
141 86 Stockholm, Sweden.
||Department of Medicine, 
University of California,  
Los Angeles,  
California 90095, USA.
¶Department of Pathology, 
Microbiology and Immunology, 
Vanderbilt University School 
of Medicine, Nashville, 
Tennessee 37232, USA.
Correspondence to F.-D.S.  
e-mail: fshi66@gmail.com
doi:10.1038/nri3065
Corrected online  
18 November 2011
Organ-specific features of  
natural killer cells
Fu-Dong Shi*‡, Hans-Gustaf Ljunggren§, Antonio La Cava|| and Luc Van Kaer¶
Abstract | Natural killer (NK) cells can be swiftly mobilized by danger signals and are among 
the earliest arrivals at target organs of disease. However, the role of NK cells in mounting 
inflammatory responses is often complex and sometimes paradoxical. Here, we examine the 
divergent phenotypic and functional features of NK cells, as deduced largely from experimental 
mouse models of pathophysiological responses in the liver, mucosal tissues, uterus, pancreas, 
joints and brain. Moreover, we discuss how organ-specific factors, the local microenvironment 
and unique cellular interactions may influence the organ-specific properties of NK cells.
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Natural killer cells
(NK cells). Cytotoxic 
lymphocytes of the innate 
immune system. These cells 
have an important role in host 
defence against many 
intracellular pathogens and 
some tumours, regulate the 
development of adaptive 
immunity, and control the 
homeostasis of other immune 
cells. Human NK cells express 
the surface marker CD56, and 
mouse NK cells express the 
surface markers DX5 (CD49b) 
and, in some mouse strains (for 
example, C57BL/6), NK1.1 
(CD161).
Systemic NK cells
NK cell subsets. NK cells can be divided into func-
tionally distinct subsets, which differ between 
humans and mice. Human NK cells can be func-
tionally classified based on the levels of CD56 and 
CD16 expression. Most circulating NK cells are 
CD56lowCD16+, and can kill target cells and pro-
duce cytokines following specific recognition of 
their targets31,32. By contrast, CD56hiCD16– NK cells, 
which are the predominant NK cell subset in periph-
eral lymphoid organs, produce large amounts of 
cytokines — including interferon-γ (IFNγ), tumour 
necrosis factor (TNF) and granulocyte–macrophage 
colony-stimulating factor (GM-CSF) — follow-
ing stimulation by pro-inflammatory cytokines and 
acquire cytotoxicity only after prolonged activa-
tion31,32. It has been shown that the CD56hiCD16– 
NK cells can differentiate into CD56lowCD16+ NK cells, 
and recent studies have revealed that CD56lowCD16+ 
NK cells can undergo further differentiation and 
functional modification with time33–35.
Mouse NK cells share many characteristics with 
human NK cells, but the lack of CD56 expression 
and other surface markers on mouse NK cells makes 
it difficult to identify functionally comparable NK 
cell populations in mice. Nevertheless, mouse NK 
cells can be classified based on expression of CD11b 
(also known as αM integrin), CD27, CD127 and B220 
(REFS 36–38). There is evidence that CD11bhiCD27+ 
and CD11bhiCD27– NK cell subsets in mice differ in 
the expression of activating and inhibitory receptors 
and chemokine receptors, with the CD11bhiCD27+ 
NK cell subset exhibiting the highest levels of both 
cytokine production and cyto toxicity39. Mouse NK 
cells that express the interleukin-7 (IL-7) recep-
tor CD127 resemble human CD56hiCD16– NK cells 
in that they produce copious amounts of cytokines 
and only acquire cytotoxic activities after pro-
longed activation. Furthermore, B220+CD11c+ NK 
cells are enriched in secondary lymphoid tissues 
and secrete higher levels of IFNγ than other mouse 
NK cells36–38.
Table 1 | Organ-specific determinants that can influence NK cell function*
Organ-
specific 
determinants 
Liver Mucosal tissues 
and skin
Uterus Pancreas Joints Brain
Chemokines Kupffer cell-derived 
CCL2, CXCL4, CXCL9, 
CXCL11, CXCL6 and 
CCL3 (Hs/Mm)16
Lung: CCR2,  
CXCR3 and 
CX
3
CR1 ligands 
(Mm)16
CXCL12  
(Hs/Mm)74–82
CXCL10 (Mm)86 CCR2 and CCR5 
ligands (Hs)93,94
Neuron-derived 
CX
3
CL1 and 
CX
3
CR1 expression 
on microglia 
(Mm)10
Skin: TIG2, CXCR3 
ligands and CCR5 
ligands (Hs)65
Unique 
cellular 
components
Kupffer cells, 
hepatic stellate 
cells, hepatocytes and 
NKT cells (Hs/Mm)42,52
Gut: DCs adjacent 
to crytopatches; 
close proximity to 
epithelial stem cells 
and Paneth cells 
(Hs/Mm)67,68
Invading 
trophoblasts; 
decidual stromal 
cells (Hs/Mm)71,72
β-cells 
expressing RAE1 
(an NKG2D 
ligand) and 
ligands for PD1 
(Mm)85,88
Osteoclasts, 
macrophages and 
monocytes  
(Hs/Mm)13,97
Microglia, 
astrocytes and 
neuronal cells  
(Hs/Mm)1,106,109
Skin: keratinocytes 
(Hs)63
Soluble 
components
Abundance of IL-12 
and IL-18; temporal 
IL-10 increase; 
frequent exposure to 
LPS (Hs/Mm)42,53–55
Gut: IL-1 and IL-23 
derived from DCs 
(Hs/Mm)68
TGFβ derived 
from stromal  
cells (Hs)81;  
IL-15 (Hs/Mm)74; 
stem cell factor 
(Mm)17
Effector 
T cell-derived 
cytokines and 
T
Reg
 cell-derived 
cytokines (Mm)6,85
M-CSF, RANKL, 
IL-12, IL-15  
and IL-18  
(Hs/Mm)13,95,97–99
Neurotransmitters; 
arrays of cytokines; 
proteins released 
by CNS-resident 
cells (Hs/Mm)1Lung: IL-15 from 
lung macrophages 
(Mm)64
Skin: CCL5 and 
CXCL10 from 
keratinocytes (Hs)68
Anatomical 
constituents
Exposure to food 
antigens and microbial 
products; perfusion 
with blood from 
the circulation and 
intestine; thin-walled 
sinusoids  
(Hs/Mm)28,42,43
Gut: exposure 
to commensal 
microflora (Hs/Mm)68
Mesometrial 
lymphoid 
aggregate of 
pregnancy  
(Hs/Mm)71
β-cells in the islets 
of Langerhans  
(Hs/Mm)127
Relative 
immune-privilege 
in normal 
conditions  
(Hs/Mm)13
Distinctive blood–
brain barrier in 
healthy conditions; 
neuro–immune–
endocrine axis  
(Hs/Mm)2,100,128
CCL, CC-chemokine ligand; CCR, CC-chemokine receptor; CNS, central nervous system; CX
3
CL, CX
3
C-chemokine ligand; CX
3
CR, CX
3
C-chemokine receptor;  
CXCL, CXC-chemokine ligand; CXCR, CXC-chemokine receptor; DC, dendritic cell; IL, interleukin; LPS, lipopolysaccharide; M-CSF, macrophage colony-stimulating 
factor; NK, natural killer; NKG2D, natural killer group 2, member D; NKT, natural killer T; PD1, programmed cell death protein 1; RAE1, retinoic acid early inducible 1; 
RANKL, receptor activator of NF-κB ligand; TGFβ, transforming growth factor-β; TIG2, tazarotene-induced gene 2 (also known as chemerin); T
Reg
, regulatory T. *‘Hs’ 
indicates evidence found in humans, ‘Mm’ indicates evidence found in mice, and ‘Hs/Mm’ indicates evidence found in both humans and mice. 
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Type 1 diabetes
A form of diabetes caused by 
autoimmune destruction of 
insulin-producing pancreatic 
β-cells. Autoimmune 
destruction is predominantly 
mediated by CD8+ T cells,  
but natural killer cells may 
affect disease outcome.
Rheumatoid arthritis
A systemic inflammatory 
disorder that may affect many 
tissues and organs, but 
principally attacks synovial 
joints. The disease process 
produces an inflammatory 
response of the synovium 
(synovitis), secondary to 
hyperplasia of synovial cells, 
excess synovial fluid and the 
development of pannus in the 
synovium. The pathology of 
the disease process often leads 
to the destruction of articular 
cartilage and ankylosis of  
the joints.
Kupffer cell
Also known as Browicz–Kupffer 
cells, Kupffer cells are 
specialized macrophages that 
line the walls of the liver 
sinusoids.
More recently, NKp46 (also known as NCR1) has 
been identified as a common marker for human and 
murine NK cells. However, some subsets of innate 
lymphocytes that are distinct from NK cells have also 
been found to express NKp46 (BOX 1).
NK cell activation. NK cells are activated by target cells 
following the detection of missing or altered expression 
of self MHC class I molecules. NK cell activation can 
occur through three mechanisms: by engagement of the 
Fc portion of IgG antibodies that decorate cells; by the 
sensing of altered molecules on stressed cells; or by an 
inflammatory environment that is rich in cytokines, such 
as IL-12 or type I IFNs40,41. Cytotoxicity against infected 
or transformed cells and production of cytokines are the 
main effector functions of NK cells.
NK cells in the liver
Homing of NK cells to the liver. The liver represents 
a unique immunological environment, in which con-
stant exposure to gut-derived antigens does not result 
in inflammation. In the liver, NK cells are preferentially 
located in the hepatic sinusoids, often adhering to the 
endothelial cells42. In mice, 5–10% of hepatic lympho-
cytes are NK cells, whereas, strikingly, up to 30–50% of 
all human hepatic lymphocytes are NK cells. Moreover, 
studies in mice have shown that the number of NK cells 
changes substantially in different experimental models 
of liver diseases. For example, mice infected with viral 
pathogens show profound accumulation of NK cells 
in the liver28,43. Likewise, administration of polyI:C 
(polyinosinic–polycytidylic acid; a synthetic version 
of double-stranded RNA) also induces NK cell accu-
mulation in the liver. The chemokines CCL2, CCL3 
(also known as MIP1α) and CXC-chemokine ligand 10 
(CXCL10), which are produced by liver-resident 
cells, can recruit NK cells expressing CCR1, CCR2, 
CCR3, CCR5 and CXCR3 to the liver under various 
pathological conditions16.
Hepatic NK cell phenotype. Whereas CD11b+CD27– 
NK cells predominate in the peripheral blood of mice, 
CD11b–CD27+ NK cells are found at greater proportions 
in the liver44. Another hallmark of liver NK cells, com-
pared with NK cells in peripheral blood, is the expres-
sion of the inhibitory receptor natural killer group 2, 
member A (NKG2A), which interacts with the MHC 
class I-related protein Qa-1 in mice (HLA-E in humans). 
Expression of NKG2A on NK cells may contribute to 
liver tolerance42.
The characteristics of NK cells in different organs 
may reflect their ability to adapt to different micro-
environments. In support of this notion, splenic NK 
cells can migrate to the liver following adoptive transfer, 
where they adopt a phenotype and function that closely 
resembles that of liver-resident NK cells44. The recent 
discovery that NK cells are capable of antigen-specific 
immunological memory in humans and mice further 
suggests that NK cells are more versatile than previously 
anticipated45–48. This is well reflected by hepatic NK cells, 
as they can acquire and retain antigen-specific memory 
against haptens and virus-derived antigens even in the 
absence of antigen persistence49,50. Memory NK cells 
specific for such antigens are enriched in the liver (FIG. 1) 
and crucially depend on expression of CXCR6, a receptor 
for the chemokine CXCL16 (which is produced by the 
endothelium of liver sinusoids50). In addition to its role in 
NK cell-mediated memory, tonic engagement of CXCR6 
protects the liver from NK cell-mediated hepatotoxicity 
by regulating the killing activity of NK cells50.
Finally, the chronic stages of hepatic infections 
with hepatitis C virus (HCV) promote the appearance 
of NK cells with increased levels of TRAIL (TNF-related 
apoptosis-inducing ligand), NKp44 (also known as 
NCR2), NKG2C and CD122 (REFS 49,50).
Crosstalk between NK cells and liver cells. NK cells may 
assist in maintaining liver tolerance through their inter-
actions with various cell types. For example, NK cells co-
cultured with hepatocytes have been described to promote 
the capacity of DCs to induce CD4+ regulatory T (TReg) 
cells51. The induction of TReg cells by DCs in the presence 
of NK cells is dependent on NKG2A engagement on 
NK cells during their co-culture with hepatocytes52.
Kupffer cells, which are mainly localized around the 
periportal regions in the liver, function as hepatic tis-
sue macrophages and are crucial for endotoxin removal 
from the blood. Treatment of Kupffer cells with lipo-
polysaccharide (LPS) results in high levels of IL-10 pro-
duction, which leads to decreased NK cell activation. 
It has been suggested that IL-10-mediated induction 
of NKG2A in liver NK cells might regulate liver NK 
cell function42 (FIG. 1). Although the timing and physio-
logical circumstances under which IL-10 is released by 
Kupffer cells require further investigation, it is presumed 
Box 1 | Innate lymphoid cells
Recent studies have identified several subsets of innate 
lymphoid cells (ILCs) that are developmentally related 
and evolutionarily conserved124. This family of cells 
includes natural killer (NK) cells, lymphoid tissue-inducer 
(LTi) cells (which produce interleukin-17 (IL-17) and/or 
IL-22), natural helper cells and nuocytes (which produce 
IL-5 and IL-13), and cells with characteristics of both 
NK cells and LTi cells. These latter cells, which have been 
referred to as NK-like cells or ILC22 cells, share with 
NK cells the expression of the natural cytotoxicity 
receptor NKp46 (but not NK1.1) and with LTi cells the 
expression of retinoic acid receptor-related orphan 
receptor-γt (RORγt). However, although NK cells 
generally produce interferon-γ and are cytotoxic, 
NKp46+RORγt+ ILCs produce IL-22 and are non-cytotoxic. 
Several subsets of ILCs are enriched in mucosal tissues, 
particularly in the gut.
NK cells have a crucial role in antiviral immunity; 
LTi cells are important for the development of lymph 
nodes during embryogenesis, tissue remodelling, 
homeostasis of epithelia and host defence; and natural 
helper cells and nuocytes have been implicated in 
immunity to extracellular parasites and in the 
development of asthma. However, the functions of 
NKp46+RORγt+ ILCs remain unclear.
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Figure 1 | Unique effector properties of NK cells in the liver. a | CC-chemokine ligand 2 (CCL2), CCL3, 
CXC-chemokine ligand 10 (CXCL10) and sphingosine-1-phosphate (S1P)125 derived from Kupffer cells and other hepatic 
cells attract natural killer (NK) cells to the inflamed liver. b | Hepatic NK cells reside in distinctive, thin-walled sinusoids, 
where Kupffer cells and other lymphocytes are also located. Hepatic NK cells face the challenging task of balancing 
immunity to multiple hepatotropic viruses and bacteria with tolerance to food and self antigens. In the steady state, 
commensal-derived lipoteichoic acid (LTA) and lipopolysaccharide (LPS) that arrive in the liver from the gut through the 
portal vein ligate Toll-like receptor 2 (TLR2) and TLR4, respectively, on Kupffer cells, triggering the release of interleukin-10 
(IL-10)126. IL-10 in turn renders NK cells hyporesponsive to IL-12 and IL-18 and promotes tolerance in the liver. In addition, 
expression of the inhibitory receptor natural killer group 2, member A (NKG2A) is increased, whereas expression of the 
activating receptor LY49 is decreased on NK cells. c | During viral infection, double-stranded RNA (dsRNA) ligates TLR3 
and triggers Kupffer cells to release IL-6 and IL-18, which in turn activate NK cells and boost their killing activity. This is 
reflected by the phenotype of hepatic NK cells, which is characterized by the expression of high levels of TNF-related 
apoptosis-inducing ligand (TRAIL), perforin and granzymes, and a lack of LY49. Activated hepatic NK cells can lyse 
hepatocytes or stellate cells via TRAIL-dependent pathways during hepatitis B virus infection or fibrosis, respectively. 
Thus, Kupffer cells appear to have a dual role in shaping hepatic NK cell phenotype and function. Hepatic NK cells are  
also subjected to the influence of interferon-γ (IFNγ) released by natural killer T (NKT) cells. Hepatic NK cells can acquire 
memory to antigens derived from influenza virus, vesicular stomatitis virus and HIV-1 (not shown). CCR, CC-chemokine 
receptor; CXCR, CXC-chemokine receptor; S1PR, S1P receptor.
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Natural killer T cells
(NKT cells). A subset of T cells 
that are specific for lipid or 
glycolipid antigens bound to 
the MHC class I-related protein 
CD1d. Most NKT cells, which 
are referred to as type I or 
invariant NKT (iNKT) cells, 
express an invariant T cell 
receptor-α chain (Vα14–Jα18 
in mice or Vα24–Jα18 in 
humans) together with various 
natural killer cell surface 
markers, such as NK1.1. 
NKT cells have a regulatory 
role during an immune 
response, bridging the innate 
and adaptive immune systems. 
iNKT cells can be most easily 
identified with multimeric 
CD1d molecules loaded with 
iNKT cell agonists, such as 
α-galactosylceramide.
that Kupffer cells produce IL-10 to downregulate the 
immune responses orchestrated by NK cells and other 
immune cells during late stages of inflammation to avoid 
bystander hepatic damage.
Soluble factors that shape NK cell phenotype in liver. The 
presence of IFNα, IFNγ, IL-2, IL-6, IL-12 and IL-18 in 
the inflamed liver largely contributes to an activated phe-
notype of NK cells, whereas IL-15 and IL-2 may sustain 
the survival and activation of these cells (FIG. 1). Among 
the liver-resident cells that can provide a source of these 
cytokines, hepatic natural killer T cells (NKT cells) can 
release large amounts of IFNγ, and Kupffer cells primar-
ily release CCL2, IL-6 and other acute pro-inflammatory 
mediators (FIG. 1). As mentioned above, Kupffer cells can 
also release IL-10 (REF. 53), which induces expression of 
NKG2A51. The liver encounters relatively high levels of LPS 
derived from the gut, which could be potentially harmful. 
Interestingly, it has been reported that crosstalk between 
Toll-like receptor (TLR) and complement receptor signal-
ling pathways inhibits IL-12 production, and this may have 
a role in dampening excessive NK cell activation54,55.
Role of hepatic NK cells in disease. Chronic liver disease 
is often associated with the development of fibrosis, a 
wound-healing process. Fibrosis is characterized by the 
formation of new blood vessels, sinusoidal remodelling 
and pericyte (stellate cell) proliferation56. Hepatic stellate 
cells are activated following the phagocytosis of apop-
totic bodies and cell debris, leading to their differentia-
tion, proliferation and pro-fibrotic progression. NK cells 
have been suggested to be involved in hepatic stellate cell 
death, as depletion of NK cells leads to enhanced fibrosis 
in a mouse experimental model42. Interestingly, of the 
many pro-apoptotic molecules investigated in activated 
hepatic stellate cells, the upregulation of TRAIL recep-
tors, which can bind NK cell-derived cytotoxic ligands 
may be crucial57.
The finding that NKG2A expression is increased on 
NK cells from patients chronically infected with HCV 
suggests a role for these cells in maintaining the persistent 
viral infection58,59, possibly by inhibiting antiviral T cell 
responses and facilitating pathogen persistence. Other 
studies have suggested that hepatic NK cells may contrib-
ute to innate resistance to HCV infection via increased 
expression of NKp30 (also known as NCR3)60. Finally, 
liver NK cells might contribute to the therapeutic activi-
ties of IFNα against hepatitis B virus (HBV) and HCV 
infection. In addition to its direct antiviral effects, IFNα 
treatment might affect NK cell activity61. Transcriptional 
profiling studies using gene arrays identified TRAIL 
as one of the most significantly upregulated genes in 
NK cells after IFNα stimulation. IFNα-stimulated NK 
cells killed HCV-infected hepatoma cells in a TRAIL-
dependent manner. These findings suggest that IFNα-
induced TRAIL expression on NK cells may be associated 
with control of HCV infection61.
Thus, steady-state hepatic NK cells promote liver 
tolerance and contain a population with memory-like 
features. Following viral infection, chemokines that are 
produced by liver-resident cells recruit more NK cells to 
the liver, and these cells acquire an activated phenotype to 
control viral infection. Crosstalk with liver-resident cells 
restrains NK cell-mediated cytotoxicity following viral 
clearance to avoid bystander tissue damage. However, 
during chronic liver infections, NK cells promote the per-
sistence of the pathogen and liver injury while inhibiting 
liver fibrosis and tissue regeneration.
NK cells in mucosal tissues and the skin
NK cell homing to the lung, skin and gut. Interpretation 
of studies performed with NK cells in mucosal tissues 
is complicated by the fact that many studies often have 
not been able to distinguish bona fide NK cells from 
NKT cells and the growing population of innate lym-
phoid cells (ILCs) that are particularly prevalent in 
the gut-associated lymphoid tissue (GALT) (BOX 1). 
Nevertheless, based on the available evidence, NK cells 
represent a major lymphocyte subset in the healthy lung 
(accounting for ~10% of all lymphocytes in the lung in 
mice)16, and are also present in healthy skin in humans62 
and in the GALT of humans and mice65.
In humans, infection with Staphylococcus aureus 
triggers a vigorous NK cell influx into the broncho-
alveolar space64. Ligation of diverse chemokine receptors, 
including CCR2, CXCR3 and CX3CR1, with their corre-
sponding ligands recruits NK cells to the lung during 
various pathogen encounters16.
In acute skin lesions, such as psoriatic plaques in 
human patients, 5–8% of the infiltrating cells are CD3–
CD56+ NK cells, which are mostly localized in the mid 
and papillary dermis63. Skin NK cells express high levels 
of the chemokine receptors CXCR3 and CCR5, inter-
mediate amounts of CXCR1, CCR6, chemokine-like 
receptor 1 (also known as CHEMR23) and CCR8, and 
low levels of CCR1, CCR2, CCR4, CCR7 and CX3CR1 
(REF. 65). Moreover, they home to the skin, directed by 
CXCL10 and CCL5 (REF. 63) (TABLE 1).
In the intestine, NK cells are found predominantly 
within the lamina propria and are rare in lymphoid 
aggregates, although they can be found in the para-
follicular region of caecal lymphoid patches, Peyer’s 
patches and mesenteric lymph nodes65.
NK cell phenotype in mucosal tissues and the skin. 
NK cells generated in vitro from lung NK cell progeni-
tors differ substantially from NK cells generated from 
bone marrow-derived NK cell progenitors with regard 
to expression of members of the LY49 family of NK cell 
receptors. Specifically, lung NK cells express multiple 
LY49 receptors, whereas most NK cells that develop 
from bone marrow-derived progenitors express CD94–
NKG2 heterodimers but not LY49, suggesting a major 
impact of the microenvironment on NK cell devel-
opment66. During S. aureus infection, lung NK cells 
produce increased amounts of TNF64.
In addition to their distinct patterns of chemokine 
receptor expression, NK cells in the skin of patients 
with psoriatic lesions exhibit a CD56hiCD16–CD158b– 
phenotype, fail to express the skin-homing cutaneous 
lymphocyte-associated antigen and release abundant 
IFNγ following stimulation63.
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Trophoblast layer
A layer formed by trophoblast 
cells that arise from the 
trophectoderm that surrounds 
the blastocyst. The trophoblast 
layer attaches the embryo to 
the uterus and forms a part  
of the placenta.
A major challenge in identifying gut NK cells lies in 
the difficulty in discriminating these cells from other gut 
ILCs. A subset of gut ILCs expresses NKp46, and among 
this subset one fraction lacks expression of retinoic acid 
receptor-related orphan receptor-γt (RORγt) and pro-
duces IFNγ67. Among gut ILCs, these NKp46+RORγt– cells 
resemble conventional NK cells in several respects, such as 
in the expression of several NK cell receptors and various 
molecules that are required for NK cell-dependent cyto-
toxicity63, and thus these cells are likely to be bona fide gut 
NK cells. However, adding to the complexity is the obser-
vation that, whereas RORγt expression is stable in ‘non-
NK’ NKp46+RORγt+ cells in the small intestine, RORγt 
expression can be lost in these cells in the colon, leading to 
a population of IFNγ-polarized NKp46+RORγt– cells that 
are phenotypically indistinguishable from gut NK cells67.
Crosstalk between NK cells and mucosal tissue- or skin-
resident cells. In the lung, alveolar macrophage-derived 
IL-15 supports NK cell proliferation and, conversely, lung 
macrophages show improved phagocytosis of S. aureus 
in the presence of NK cells64. Similarly, there appears 
to be a reciprocal relationship between skin-infiltrating 
NK cells and keratinocytes. Keratinocytes may provide 
a major source of CCL5 and CXCL10 to recruit NK cells, 
and skin-resident NK cells release large amounts of IFNγ 
and efficiently activate keratinocytes63. In the gut, sig-
nals emanating from DCs, epithelial cells and luminal 
contents constantly regulate GALT development and 
function, thereby contributing to the maintenance of a 
‘tolerogenic’ status to innocuous antigens and commen-
sal flora while initiating immune responses and tissue 
reparative mechanisms that restrain pathogen invasion67. 
For example, IL-23 enhances the production of IL-22 
by NKp46+RORγt+ cells67,68, and this may function to 
preserve and restore epithelial barrier integrity67.
Role of mucosal NK cells in disease. NK cells, including 
those in the gut and other mucosal lymphoid organs, are 
thought to protect against infection by viruses and other 
intracellular pathogens. For example, within 24 hours 
of infection with orally administered Listeria mono­
cytogenes, IFNγ production is induced by NK cells in the 
small intestine69. IFNγ production peaks at 48 hours post- 
inoculation in this model. Importantly, blocking IFNγ, 
but not IL-22, with neutralizing antibodies induces signif-
icant increases in bacterial loads in the GALT69. However, 
this does not exclude an important role for IL-22 in other 
bacterial infections or in other forms of tissue injury69,70.
In summary, NK cells are detected in healthy mucosal 
tissues and the skin. In response to infection, more NK 
cells are recruited to the lung, the gut and the skin, and 
these cells acquire an activated phenotype, which is 
essential for pathogen clearance. Moreover, in the gut, 
classical NK cells together with ILCs appear to control 
inflammatory responses.
NK cells in the uterus
NK cell homing to the uterus. NK cells are abundant 
in the decidua — the endometrium of the pregnant 
uterus that forms the maternal part of the placenta. 
There, uterine NK cells are thought to control endo-
metrial tissue remodelling, vascular function and the 
formation of a placenta in the uterus71,72. Several studies 
have described the kinetics of uterine NK cell accu-
mulation in pregnant mice72,73. Following fertilization 
and implantation, NK cells accumulate initially in the 
decidua basalis, which is subjacent to the trophoblast 
layer, and later in the mesometrial lymphoid aggre-
gate of pregnancy, a lymphoid structure that tran-
siently forms between the two layers of myometrial 
smooth muscle. Uterine NK cell numbers peak at mid- 
gestation (9–10 days) and decline in the last 5 days of 
pregnancy73. Uterine NK cells can either develop in situ 
or migrate from the peripheral blood through a CXCR4- 
and CXCL12-dependent mechanism (reviewed in 
REF. 74) (TABLE 1).
Uterine NK cell phenotype. During pregnancy, the 
human uterine decidua is dominated by the presence 
of CD56hiCD16– NK cells75. In the mouse, two distinct 
subsets of CD3–CD122+ NK cells have been described in 
the uterus at mid-gestation76 (TABLE 2). The smaller sub-
set expresses phenotypic markers of peripheral NK cells 
and might therefore represent peripheral NK cells that 
have recently been recruited into the uterus. The larger 
subset lacks NK1.1 expression and reacts with Dolichus 
biflorus agglutinin, which specifically identifies uterine 
NK cells in the mouse. Uterine NK cells express a unique 
repertoire of MHC class I-binding receptors, activation 
markers and adhesion molecules. The unique LY49 
receptor repertoire of mouse uterine NK cells suggests 
that they develop within the uterus and that the local 
microenvironment may shape the LY49 receptor reper-
toire76. Similarly, NK cells in the human uterine mucosa 
have recently been characterized and found to resemble 
unique early developmental stages of human NK cell 
differentiation77.
Crosstalk between uterine NK cells and trophoblasts 
during pregnancy. The function of uterine NK cells 
is still not clear, but it appears that they interact with 
invading trophoblasts, and this interaction results in 
the release of factors that modify the uterine spiral 
arteries. This ‘physiological’ inflammatory process 
is important as it increases the blood supply to the 
mouse fetus71,78,79. Moreover, uterine NK cell-derived 
IFNγ is needed for vascular modifications to occur 
during pregnancy78. Although mice lacking uterine 
NK cells or components of the IFNγ pathway do not 
exhibit increased fetal loss, they show several abnor-
malities during pregnancy, including reduced decidual 
cellularity and inadequate modifications of the spiral 
arteries73.
In addition, the regulation of NK cell activation is 
crucial for normal placentation and hence a successful 
pregnancy. Interestingly, human immunogenetic studies 
have suggested that interactions between fetal HLA-C 
molecules and killer cell immunoglobulin-like receptors 
(KIRs) on uterine NK cells are important for reproduc-
tive success in humans, possibly through tuning the 
threshold for NK cell activation80.
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Soluble factors that shape NK cell phenotype in the 
uterus. Transforming growth factor-β (TGFβ) produced 
by decidual stromal cells can reduce CD16 expression 
on NK cells, thereby impairing antibody-dependent cel-
lular cytotoxicity (ADCC)81. CXCL12 is produced in the 
decidua, particularly by extravillous trophoblasts, and 
attracts peripheral NK cells towards the decidua82; on the 
other hand, the presence of IL-15 and stem cell factors 
may support NK cell development in situ74 (TABLE 1).
Role of uterine NK cells in pregnancy disorders. 
Uterine NK cell activation following interaction with 
invading trophoblasts has been associated with several 
pregnancy disorders. A seminal study described how 
a particular combination of fetal HLA-C molecules 
and maternal inhibitory NK cell receptors was associ-
ated with a predisposition for pre-eclampsia83. More 
recently, such studies have been extended to recur-
rent miscarriage and fetal growth restriction, reveal-
ing a common uterine NK cell-mediated mechanism 
underlying these pregnancy disorders84. Importantly, 
this study also showed that mothers with uterine NK 
cells that express activating and inhibitory NK cell 
receptors with similar specificities are less likely to suf-
fer from unsuccessful pregnancy. Although data from 
human population genetics studies have provided 
interesting insights into the factors controlling inter-
actions between uterine NK cells and trophoblasts of 
fetal origin, functional studies in humans are challeng-
ing. Thus, despite differences in placentation between 
humans and mice71, mice may provide an important 
model for studying the biology of uterine NK cells.
In summary, uterine NK cells can either develop 
in situ or migrate to the decidua after being attracted by 
locally produced chemokines. Their receptor repertoire 
suggests that their activation has to be tightly regulated to 
ensure normal pregnancy. Moreover, mouse and human 
studies suggest that crosstalk between uterine NK cells 
and trophoblasts contributes to vascular modifications 
during pregnancy.
NK cells in the pancreas
NK cell homing to the pancreas. NK cells are present 
not only in the pancreas of diabetes-prone non-obese 
diabetic (NOD) mice but also in the pancreas of mouse 
strains that are not susceptible to the development of 
Table 2 | Unique features of NK cells in distinct organs*
Cell features 
and functions
Liver Mucosal tissues and 
skin
Uterus Pancreas Joints Brain
Receptor 
expression
NKG2A ↑, LY49 ↑, 
CD56low and 
CD16 ↓  
(Hs/Mm)44,49,50 
Gut: RORγt+LIN–, 
RORγt+NKp46+NK1.1int, 
CD127+NKp46low, 
CD122intc-Kit+ and KIR– 
(Hs)65,67–69; LY49– (Mm)68 
CD16–CD56hi 
(Hs)75; NKp46+ 
(Hs/Mm)75; 
CD3–CD122+, 
LY49+, NK1.1– and 
DX5– (Mm)76,79
KLRG1 ↑; NK cells 
from NOD mice 
express more NKC 
gene products 
than NK cells from 
B6.H-2g7 mice; 
CD25 and CD69 
(Mm)6,85
CD56hiCD16– ↑, 
CD94–NKG2A ↑ 
(Hs)87,92,95,96; 
RANKL+, chemokine 
receptors ↑  
(Hs/Mm)13,99; 
M-CSFR+, adhesion 
molecules ↑ 
(Mm)13,97,98
NKG2A ↑ (Mm)11,12; 
nicotinic 
acetylcholine 
receptors ↑ (Mm)‡
Lung: LY49hi (Mm)64,66
Skin: CD56hiCD16–
CD158b– (Hs)63
Effector 
molecule 
expression
NKp44+, NKG2C+, 
TRAIL ↑, perforin 
and granzymes ↑ 
(Mm)44,49,50
Gut: IL-22+, IL-17+,  
IFNγ– and perforin ↓  
(Hs/Mm)67
CXCL8 and 
CXCL12 ↑ (Hs)82; 
IFNγ, VEGF and 
PLGF ↑ (Mm)74,78
PD1+ and LAMP1+ 
(Mm)85,88
Granzymes and 
IFNγ (Hs/Mm)13,87,92
IFNγ, perforin 
and granzymes ↑ 
(Mm)11,12
Lung: factors that 
enhance macrophage 
function (Mm)64
Skin: IFNγ  (Hs)63
Cytotoxicity 
and 
proliferation
Increased early, 
decreased at 
later stages  
(Hs/Mm)42
Gut: reduced or absent 
(Hs/Mm)67,68
ADCC and 
cytotoxicity 
decreased (Hs)81
Proliferation and 
degranulation 
increased early 
and decreased at 
later stages (Mm)85
Increased (Mm)13 Increased 
cytotoxicity 
against microglia 
(Mm)11,12
Other 
functions
Crosstalk with 
Kupffer and 
NKT cells  
(Hs/Mm)42; 
promote T
Reg
 cells 
(Mm)51 
Control inflammation 
(Hs/Mm)67,84
Regulate 
endometrial 
remodelling, 
angiogenesis and 
implantation  
(Hs/Mm)71; uterine 
NK cell-derived 
IFNγ modifies 
vascularity (Mm)78
Reciprocal 
interactions with 
effector and 
T
Reg
 cells (Mm)6
Promote formation 
of osteoclasts; 
colocalize with 
monocytes and 
promote their TNF 
production (Mm)13
Condition the 
CNS; release 
cytokines; 
suppress 
myelin-specific 
T
H
17 cells (Mm)11,12
Gut: T
H
17 cell-like 
functions; respond 
to DC-derived IL-23 
and IL-1, but not IL-15; 
sustain lymphoid tissue 
integrity; promote 
tissue repair  
(Hs/Mm)67,68
ADCC, antibody-dependent cell-mediated cytotoxicity; CNS, central nervous system; CXCL, CXC-chemokine ligand; DC, dendritic cell; IFNγ, interferon-γ; 
IL, interleukin; KLRG1, killer cell lectin-like receptor subfamily G member 1; LAMP1, lysosomal-associated membrane protein; LIN–, lineage negative; M-CSF, 
macrophage colony-stimulating factor; NK, natural killer; NKC, natural killer gene complex; NKG2, natural killer group 2; NKT, natural killer T; NOD, non-obese 
diabetic; PLGF, placental growth factor; RANKL, receptor activator of NF-κB ligand; T
H
17, T helper 17; TNF, tumour necrosis factor; TRAIL, TNF-related 
apoptosis-inducing ligand; T
Reg
, regulatory T; VEGF, vascular endothelial growth factor. *‘Hs’ indicates evidence found in humans, ‘Mm’ indicates evidence found in 
mice, and ‘Hs/Mm’ indicates evidence found in both humans and mice. ‡Unpublished observations (F.-D.S.).
R E V I E W S
664 | OCTOBER 2011 | VOLUME 11  www.nature.com/reviews/immunol
© 2011 Macmillan Publishers Limited. All rights reserved
diabetes85. This indicates that NK cells can be recruited 
to the pancreas in the absence of profound inflamma-
tion. Nevertheless, the severity of T1D in NOD mice 
correlates with increased numbers and early entry of 
NK cells into the pancreas5,6,85, suggesting a disease- 
promoting role for these infiltrating NK cells. Importantly, 
one study showed that NK cells accumulate before T cells 
in the islet infiltrates85. NK cells might be recruited to the 
pancreas by chemokines such as CXCL10 (a ligand for 
CXCR3 on NK cells) and CCL5 (a ligand for CCR5 on 
NK cells), which can be produced by multiple cell types, 
including pancreatic β-cells (TABLE 1), and their num-
bers are increased in the pancreas of NOD mice in an 
accelerated model of T1D86.
Pancreatic NK cell phenotype. Molecular, phenotypic and 
functional characteristics of NK cells in the pancreas 
and spleen have been compared between diabetes-prone 
NOD mice and diabetes-resistant mice5,85. Microarray 
studies revealed that the NK cell gene complex, which 
encodes a set of NK cell receptor genes, is expressed dif-
ferently in diabetes-prone NOD mice versus diabetes-
resistant B6.H-2g7 mice (which are congenic for the NOD 
MHC region). Immune phenotyping analyses further 
indicated that pancreatic NK cells from NOD mice share 
phenotypic characteristics with pancreatic NK cells from 
non-diabetic strains, but display increased levels of the 
activation markers CD69 and CD25, and of surface killer 
cell lectin-like receptor G1 (KLRG1), which is a marker 
for mature NK cells that have undergone proliferation85. 
Furthermore, a subset of pancreatic NK cells from young 
NOD mice produced IFNγ and expressed the lysoso-
mal marker lysosome-associated membrane protein 1 
(LAMP1; also known as CD107a)85, which is a marker 
for NK cell degranulation (TABLE 2).
However, proliferating and activated NK cells were 
detected only in the early pre-diabetic infiltrates85. During 
the later stages of diabetes development, most pancreatic 
NK cells of NOD animals became hyporesponsive, as 
reflected by diminished cytokine secretion and a lower 
capacity to degranulate in response to antibodies specific 
for activating receptors, and in response to activation by 
phorbol 12-myristate 13-acetate (PMA) and ionomycin. 
It was thus proposed that pancreatic NK cells from 
NOD mice initially mediate pro-inflammatory effector 
functions, but later become hyporesponsive owing to 
exhaustion or regulation85.
Crosstalk between NK cells and β-cells. Experiments in 
which splenic NK cells from NOD mice were transferred 
into recombination activating gene (RAG)- and com-
mon cytokine receptor γ-chain (γc)-deficient NOD mice 
(which lack B cells, T cells and NK cells) showed that NK 
cells migrate to the pancreas and upregulate CD69 and 
KLRG1 expression85. This suggests that the local micro-
environment in the pancreas of NOD mice, in the absence 
of profound inflammation and adaptive immune cells, can 
recruit NK cells and regulate the phenotype of these cells. 
In addition, one study suggested that the NK cell activat-
ing receptor NKp46 can recognize ligands on β-cells that 
promote NK cell activation, which, in turn, might result in 
β-cell destruction8. Such activated NK cells might exhibit 
direct cytotoxicity against pancreatic β-cells and recruit 
other cell types, and thus have a pathogenic role during 
the early stages of diabetes development.
The hyporesponsive phenotype of NK cells that is 
observed during later stages of diabetes development 
might be partly caused by interactions between NK 
cell receptors and their ligands expressed by pancreatic 
β-cells. For example, it has been suggested that ligands 
for NKG2D — such as retinoic acid early inducible 1 
(RAE1; also known as mRNA export factor) expressed 
by pancreatic β-cells — might downregulate the expres-
sion of NKG2D and ‘turn off ’ NK cells to avoid excessive 
autoimmunity87. Furthermore, interaction of the inhibi-
tory receptor programmed cell death protein 1 (PD1) on 
pancreatic NK cells with PD1 ligands on inflamed islets 
might dampen the response of pancreatic NK cells85,88.
Soluble factors that shape NK cell phenotype in the pan-
creas. The phenotype of NK cells in the pancreas might 
be influenced by cytokines produced by other cell types. 
For example, it has been suggested that cytokines derived 
from autoreactive T cells might contribute to the hypo-
responsive phenotype of NK cells during the later stages 
of diabetes development in NOD mice87. There is also 
evidence that NK cell functions are kept in check by TReg 
cells, as ablation of CD4+FOXP3+ TReg cells in diabetes-
prone BDC2.5 T cell receptor (TCR)-transgenic NOD 
mice results in rapid activation of NK cells within the 
insulitic lesions, before the activation of effector T cells6.
Role of pancreatic NK cells in disease. A pathogenic 
role of NK cells in T1D has been supported by evidence 
derived from several animal models5–8,86,89. Depletion of 
NK cells significantly inhibited diabetes development 
in three mouse models: BDC2.5 TCR-transgenic NOD 
mice treated with cytotoxic T lymphocyte antigen 4 
(CTLA4)-specific antibodies5; transgenic NOD mice 
with pancreatic expression of suppressor of cytokine 
signalling 1 (SOCS1) that had been infected with 
coxsackievirus B4 (REF. 89); and transgenic NOD mice 
with β-cell-specific expression of IFNβ86. Furthermore, 
blockade of the NK cell activating receptor NKG2D 
prevented disease in NOD mice7, although the con-
tribution of other NKG2D-expressing cells (including 
CD8+ T cells) could not be ruled out in this model.
In addition to their pathogenic roles in autoimmune 
diabetes, NK cells can, paradoxically, exhibit protective 
functions in β-cell autoimmunity. NK cells have a cru-
cial role in mediating the capacity of complete Freund’s 
adjuvant (CFA) to protect NOD mice from diabetes90. 
NK cells also have an important role in islet allograft 
tolerance in C57BL/6 mice induced by blocking inter-
actions between CD40 and CD154 or between lympho-
cyte function-associated antigen 1 (LFA1; also known 
as αLβ2 integrin) and intercellular adhesion molecule 
(ICAM)91. It is likely, however, that these ameliorating 
effects of NK cells on autoimmunity and allograft rejec-
tion are mediated by peripheral rather than pancreatic 
NK cells, possibly through them interacting directly with 
DCs or pathogenic T cells.
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Collagen-induced arthritis
A model for human rheumatoid 
arthritis that is induced in 
susceptible strains of mice or 
rats by immunization with 
autologous or heterologous 
type II collagen in adjuvant.
K/BxN mice
K/BxN mice express a 
transgene-encoded T cell 
receptor that is specific for  
the ubiquitously expressed 
enzyme glucose-6-phosphate 
isomerase, which is presented 
by the MHC class II molecule 
H2-Ag7. These mice 
spontaneously develop joint 
inflammation with features of 
human rheumatoid arthritis. 
Interestingly, transfer of serum 
from arthritic animals into 
healthy non-transgenic animals 
induces arthritis in a highly 
reproducible and controlled 
manner.
In summary, few NK cells home to the healthy pan-
creas, and the numbers of pancreatic NK cells are sub-
stantially increased in diabetes-prone and diabetic mice. 
The local microenvironment of the pre-diabetic pancreas 
seems to induce NK cell proliferation and activation. At 
later disease stages, crosstalk between pancreatic NK cells 
and β-cells or other immune cells leads to NK cell hypo-
responsiveness. Despite their early pathogenic role in dia-
betes, NK cells have also been implicated in CFA-mediated 
diabetes protection and in islet allograft tolerance.
NK cells in the joints
NK cell homing to the joints. Whereas few NK cells are 
present in healthy joints, these cells are abundant in the 
inflamed joints of patients with rheumatoid arthritis92 
and in mice with collagen-induced arthritis13. NK cells can 
be detected in the inflamed synovial tissue at any stage of 
the disease, and they constitute up to 20% of all lympho-
cytes in synovial fluid of patients with established rheu-
matoid arthritis92. These cells express increased levels of 
the chemokine receptor CCR5 and, to a lesser extent, 
CCR2 (REF. 93). Chemokine ligands for these receptors 
have been detected in the synovial fluid of patients with 
rheumatoid arthritis94 (TABLE 1).
NK cell phenotype in the joints. Among synovial fluid 
NK cells in patients with rheumatoid arthritis, cells of 
the CD56hiCD16– phenotype predominate92,95,96, sug-
gesting that this cell population is selectively recruited 
to the inflamed synovium and/or expands there. These 
cells also express high levels of the inhibitory receptor 
NKG2A, produce granzymes and exhibit enhanced cyto-
toxicity compared with systemic NK cells87,92 (TABLE 2). 
Uniquely, NK cells in the joints of mice with collagen-
induced arthritis express receptor activator of NF-κB 
ligand (RANKL) and macrophage colony-stimulating 
factor (M-CSF)97,98, a feature that is shared with NK cells 
from patients with rheumatoid arthritis99.
Crosstalk between NK cells and other cells in inflamed 
joints. The molecular features of synovial fluid NK cells 
and their interaction with other cells in the inflamed 
joint have been investigated in animal models. NK cells 
in the inflamed joint that express RANKL and M-CSF 
are frequently juxtaposed with monocytes in the syn-
ovium of inflamed joints13 (TABLE 2). The reciprocal 
interactions between these two cell types can trigger the 
formation of osteoclasts in a process that is dependent 
on RANKL and M-CSF13.
Soluble factors that shape NK cell phenotype in joints. 
Cytokines, such as IL-12, IL-15 and IL-18, that are pro-
duced by myeloid cells in the inflamed joint can stimu-
late IFNγ production by NK cells95. These factors, in 
particular IL-15, might also contribute to the induction 
of RANKL and M-CSF in synovial NK cells13.
Role of joint NK cells in disease. Depletion of NK cells 
from mice before the induction of collagen-induced 
arthritis reduces the severity of subsequent arthri-
tis and almost completely prevents bone erosion13. 
Paradoxically, however, NK cells were shown to have a 
crucial role in protection against inflammatory arthritis 
mediated by unmethylated CpG oligodeoxynucleotides 
following transfer of serum from K/BxN mice into wild-
type mice 14. This protection required interaction of NK 
cells with DCs in lymphoid organs, resulting in reduced 
neutrophil recruitment to the joints. These observations 
suggest opposite functions of NK cells in lymph nodes 
versus inflamed joints during rheumatoid arthritis. The 
current available information is not sufficient to provide 
a clear linkage between the divergent phenotypes and 
functions of NK cells in lymphoid organs and joints. 
Differences in the triggering antigens (that is, type II 
collagen versus glucose-6-phosphate isomerase) in dif-
ferent models of arthritis and their roles in inducing NK 
cells directly or indirectly invite further investigation.
Thus, NK cells are recruited to the inflamed joints, 
where they exhibit an activated phenotype and pro-
mote osteoclast differentiation and inflammation. By 
contrast, lymph node NK cells have been suggested to 
play a crucial part in CpG-induced protection against 
inflammatory arthritis in a mouse disease model.
NK cells in the CNS
Homing of NK cells to the CNS. In the CNS, the brain 
and spinal cord are shielded from the circulating blood 
by the blood–brain barrier and the epithelial blood– 
cerebrospinal fluid barrier, respectively, which are 
formed by the tight junctions of endothelial cells and 
prevent the influx of immune cells under normal physio-
logical conditions. This view was recently challenged by 
the finding that activated T cells can breach the blood–
brain barrier and the epithelial blood–cerebrospinal 
fluid barrier to perform immune surveillance func-
tions in the CNS100. It is conceivable that peripherally 
activated lymphocytes, including NK cells, might also 
be able to penetrate the blood–brain barrier. However, 
data on the presence of NK cells in the human brain and 
spinal cord are sparse. Nevertheless, NK cells can be 
detected in mouse CNS tissues during a variety of infec-
tions, including infection by murine corona virus101, 
Semliki Forest virus102 and L. monocytogenes103. NK 
cells are also recruited to the CNS in glioma-bearing 
mice; 1 week after tumour implantation, NK cells con-
stitute approximately 50% of all leukocytes in the CNS, 
and after this peak their frequency gradually declines104. 
NK cells might be recruited to the CNS by chemokines 
such as CX3CL1 produced by neurons and CCL2 and 
CXCL10 produced by microglia, astrocytes or infiltrating 
inflammatory cells (TABLE 1).
NK cell phenotype in the CNS. The most intriguing data 
on the role for NK cells in CNS inflammation are derived 
from studies of experimental autoimmune encephalomyelitis 
(EAE). In this model, NK cells become fully activated 
and proliferate in the CNS even before the arrival of 
T cells105. Analysis of NK cells in the CNS of mice with 
EAE suggested that, compared with their peripheral 
counterparts, CNS-infiltrating NK cells upregulate the 
inhibitory receptor NKG2A and produce large amounts 
of CCL2, a chemoattractant for microglia11,12.
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Microglia
Non-neuronal cells of the 
central nervous system with 
phagocytic properties. They 
are haematopoietic cells and 
are involved in inflammatory 
and immune responses in the 
central nervous system.
Experimental autoimmune 
encephalomyelitis
(EAE). An experimental model 
for human multiple sclerosis 
that can be induced in 
susceptible animals by 
immunization with 
neuroantigens and adjuvant.
Crosstalk between NK cells and CNS-specific cell 
types. The CNS is distinguished from other organs 
with regard to the genesis and progression of inflam-
matory responses in that it harbours a unique spectrum 
of antigen-presenting cells (APCs; that is, astrocytes 
and microglia) and neuroantigens, and accommodates 
intimate interactions between the immune and nerv-
ous systems (FIG. 2). So, after homing to the inflamed 
CNS, NK cells become receptive to an array of cell-
ular components that they have not encountered in 
the periphery. These include astrocytes, microglia and 
neurons106–109, which release numerous soluble factors 
with diversified and perhaps coordinated effects on 
NK cells (FIG. 2).
The finding that NK cells in the CNS control the 
magnitude of an inflammatory response in the EAE 
model11,12 suggests that, after homing to the CNS, NK 
cells exert specific functions that affect the outcome 
of inflammation. In particular, it has been suggested 
that NK cells in the CNS can directly lyse microglia11,12. 
Microglia are macrophage-like APCs that are capable 
of priming myelin-reactive T cells, and they exert 
direct effects on neuronal or glial cells depending 
on the timing of the inflammatory process and the 
activation status of these cells105–111. Microglia serve 
as sentinels for ongoing immune responses in the 
periphery that have the potential to spread to the CNS. 
In comparison with the behaviour of other types of 
APC in the CNS during brain inflammation, activated 
microglia appear to become targets of peripherally 
activated NK cells that enter the CNS11. Such inter-
actions between NK cells and microglia are likely to 
be facilitated by the recruitment of microglia through 
CCL2 secretion by NK cells. As activated microglia 
have a crucial role in initiating and propagating path-
ogenic T cell responses during EAE, their elimina-
tion results in reduced numbers of myelin-reactive 
T helper 17 (TH17) cells in the CNS
11. Although the 
exact mechanisms remain unclear, susceptibility of acti-
vated microglia to NK cell lysis may occur through the 
Figure 2 | The brain alters NK cell phenotypes and functions. The entry of lymphocytes into the central nervous 
system (CNS) is normally shielded by the blood–brain barrier, which becomes compromised in several pathological 
circumstances. Natural killer (NK) cells are recruited to the inflamed brain by CX
3
C-chemokine ligand 1 (CX
3
CL1) 
produced by neurons. Brain-specific cell types and neurotransmitters alter the features of NK cells that migrate from 
the periphery. An array of cytokines, growth factors and neurotransmitters produced by microglial cells, astrocytes 
and neurons can influence NK cell activation and proliferation. The chemokine CC-chemokine ligand 3 (CCL3) 
attracts NK cells to the site of inflammatory foci. After acquiring new features, brain-resident NK cells lose tolerance 
to microglial cells, suppress pathogenic, myelin-reactive T helper cells and significantly attenuate the intensity of 
local inflammatory and autoimmune responses. NK cells also kill neurons infected by herpes simplex virus. In 
addition, mediators derived from neurons, microglial cells and astrocytes and multidirectional cellular interactions 
may influence NK cell tolerance and function. The combined effects of soluble factors and cellular interactions, as 
well as the timing of the immune response, may dictate NK cell activity in the CNS. ACh, acetylcholine; BDNF, 
brain-derived neurotrophic factor; CXCL10, CXC-chemokine ligand 10; EGF, epidermal growth factor; IFNβ, 
interferon-β; IL, interleukin; M-CSF, macrophage colony-stimulating factor; NGF, nerve growth factor; NO, nitric 
oxide; PGE2, prostaglandin E2; TGFβ, transforming growth factor-β; TNF, tumour necrosis factor.
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Multiple sclerosis
An inflammatory and 
demyelinating disease of the 
central nervous system that is 
primarily diagnosed in young 
adults. Clinical presentations 
are heterogeneous depending 
on the severity and location of 
central nervous system lesions.
loss of MHC class I expression on these cells11,12 (FIG. 2). 
These findings in mice are in apparent contrast with a 
recent study suggesting that human NK cells can lyse 
resting microglia but spare activated microglia in an 
in vitro culture system105. However, it remains unclear 
which NK cell subset executed this killing activity and 
how microglia were maintained within a resting state 
during this experiment.
Soluble factors that shape the NK cell phenotype in the 
CNS. Under pathophysiological conditions, an array 
of soluble factors is produced by microglia, astrocytes 
and neuronal cells (FIG. 2). Based on their effect on NK 
cells, these mediators can be categorized as inhibitory 
(such as TGFβ, IL-10 and acetyl choline) or stimula-
tory (such as ATP, UTP, glutamate, prostaglandin 
E2, H2O2, nitric oxide, IL-1β, IL-6, TNF, epidermal 
growth factor (EGF), brain-derived neurotrophic 
factor (BDNF), neurotrophin 3, neurotrophin 4, IL-3, 
IL-12 and M-CSF). So, the sequence of soluble signals 
received by NK cells, the physical location of the cell-
ular source of these factors and the balance between 
inhibitory and stimulatory signals that NK cells receive 
may all influence the functional status of NK cells in 
the inflamed CNS.
Role of CNS-specific NK cells in disease. During EAE 
in C57BL/6 mice, depletion of NK cells exacerbates 
neuro logical deficits9,11. Similarly, CX3CR1-deficient 
mice, in which homing of NK cells to the brain is 
severely impaired, develop fatal inflammatory lesions 
following EAE induction10. As the numbers of periph-
eral NK cells in these mice are comparable with those of 
wild-type mice, these results imply that a CNS-specific 
deficit in NK cells leads to aggressive inflammation and 
auto immunity in the CNS (FIG. 2). Thus, there is strong 
evidence that CNS-specific NK cells control CNS 
inflammation during EAE in mice.
These findings might be relevant to the mode of 
action of daclizumab, a humanized antibody specific 
for the IL-2 receptor α-chain (CD25). Daclizumab, 
alone or in combination with IFN preparations, con-
sistently reduces CNS lesions in patients with multiple 
sclerosis112–115. One of the immunological effects of 
daclizumab is that it can expand CD56hi NK cell popu-
lations in treated patients107. In a human–mouse chi-
maera model, it has been demonstrated that EAE can 
be ameliorated by transfusion of human NK cells11. 
As administration of NK cells directly into the brain 
appeared to achieve enhanced clinical benefits com-
pared with systemically administered cells11, these 
results suggest that NK cells within the brain may have 
an anti-inflammatory role. Furthermore, there is some 
evidence to suggest that other drugs that are currently 
used for the treatment of multiple sclerosis, such as 
IFN preparations and glatiramer acetate (a random 
polymer of the four amino acids found in myelin basic 
protein; also known as copolymer 1 or Copaxone (Teva 
Pharmaceuticals)), may achieve their clinical efficacy 
partially by inducing NK cells116,117 via a mechanism 
similar to that of daclizumab.
In addition to their protective role in autoimmune 
disease, NK cells control CNS infections. In detail, 
NK cells provide protection against encephalitis and 
demyelination induced by Theiler’s murine encephalitis 
virus118, reduce viral replication and disease following 
intracerebral infection by murine coronavirus101, and 
exacerbate immunopathology and accelerate mortality 
during Semliki Forest virus infection102.
In summary, there are no data on the presence of NK 
cells in the steady-state CNS, but NK cells have been 
shown to migrate to the inflamed CNS. Although the 
exact cellular and molecular interactions that shape NK 
cell phenotype and function in the CNS still need to be 
determined, it appears that activated NK cells have a 
protective role in the brain under the circumstances of 
ongoing inflammation, as they eliminate viral infection 
and inhibit the activation of autoimmune T cells through 
the killing of activated microglia.
Linking organ-specific NK cell features and disease
The major functions of NK cells in the liver, mucosal tis-
sues, skin, pancreas and perhaps the CNS are to amplify 
the local immune response and combat infectious 
agents. In doing so, NK cells may kill infected or trans-
formed cells. When this process becomes dysregulated, 
damage to neighbouring cells and autoimmune disease 
might ensue. Determinants for these divergent roles of 
NK cells, as exemplified here for a number of different 
organs, include the timing of immune responses, the 
different pathogens targeted by the NK cells and the NK 
cell-orchestrated immune responses. Furthermore, the 
studies discussed here raise the possibility that organ-
specific factors shape NK cell phenotype and contrib-
ute to the organ-specific functions of these cells. The 
organ-specific features of NK cells appear to be dictated 
by a number of factors that are intrinsic to a particular 
organ, including its anatomical structure, accessibil-
ity to peripheral immune cells, and the unique micro-
environment of cells and soluble factors within the organ. 
Additional determinants include inciting pathogens or 
autoantigens that induce inflammation.
Concluding remarks
We have discussed here the organ-specific features of 
NK cells and given examples of how these cells may serve 
to maintain normal health and contribute to the devel-
opment and control of inflammation in various organ-
specific diseases. There are many outstanding questions 
and future challenges in this area (BOX 2). Progress will 
be facilitated by novel approaches such as two-photon 
microscopy, which has been used to record the traf-
ficking of several types of lymphocytes to reveal the 
cellular interactions within solid organs in physiologi-
cal and pathological situations119–122. The application of 
this and other techniques to studies of NK cells in solid 
organs should reveal valuable information on the physi-
cal localization of NK cells within specific anatomical 
structures, as well as interactions with resident cellular 
components. Imaging studies in live animals may yield 
insight into the behaviour of NK cells during the course 
of organ-specific inflammation.
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